sitagliptin glp 1 agonist DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits | Military Medical Research Mechanism of action of GLP-1
Description
100 pellets were earned)
Participants were randomly assigned in a 1:1 ratio to receive either semaglutide 50 mg or a placebo once daily for 68 weeks
Over years of therapy, cumulative lean mass loss could become clinically significant, particularly in older adults at risk for sarcopenia
Adverse effects include severe nausea, severe vomiting and severe hypoglycemia (low blood sugar levels)
Similar to other medications in its class, tirzepatide functions by mimicking GLP-1
